ReviewFrontiers in oncology2025
Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Research Progress on Angiogenesis and Involution Mechanisms of Infantile Hemangioma and Its Regulation by Active Components ofInternational journal of molecular sciences · 2026Review
- Darbepoetin and Infantile Hemangioma in Premature Infants.Journal of clinical medicine · 2026Article
- Article
- Integrative Bioinformatics Analysis and Machine Learning Reveal TSPAN7 Regulates the Involution of Infantile Hemangioma via NK Cells.Clinical, cosmetic and investigational dermatology · 2026Article
- Key cellular subpopulations and mechanisms of propranolol in infantile hemangioma: insights from single-cell omics.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH), the most prevalent benign vascular tumor in neonates, typically appears several weeks after birth, undergoes rapid proliferation, and subsequently enters a prolonged phase of spontaneous involution. Recent advancements in molecular and cellular biology have revealed increasing evidence that the etiology and progression of IH arise from complex, multi-level interactions involving various factors. In this review, we examine the categorization of IH cells, analyze the pivotal roles of key molecular signaling pathways (e.g., VEGF, HIF, Notch), and elucidate the contributions of immune cells, hypoxia, the extracellular matrix, and exosome-mediated signaling within the tumor microenvironment to the angiogenic processes and regression of IH. These insights will enhance our understanding of IH pathogenesis, thereby laying the groundwork for the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.